These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10893758)

  • 1. [Type 2A multiple endocrine neoplasia with cutaneous lichen amyloidosis].
    Brändle M; Schlaeppi M; Schmid C
    Schweiz Med Wochenschr; 2000 Jun; 130(22):861. PubMed ID: 10893758
    [No Abstract]   [Full Text] [Related]  

  • 2. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis.
    Seri M; Celli I; Betsos N; Claudiani F; Camera G; Romeo G
    Clin Genet; 1997 Feb; 51(2):86-90. PubMed ID: 9111993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification and screening of a family with type 2A multiple endocrine neoplasia with DNA analysis].
    Wiesli P; Rojas J; Komminoth P; Gemsenjäger E; Furrer J
    Praxis (Bern 1994); 1999 Oct; 88(41):1667-73. PubMed ID: 10546512
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple endocrine neoplasia type 2 and the RET receptor--a disease spectrum comes of age.
    Soule S; Berman P
    S Afr Med J; 1997 Mar; 87(3 Suppl):357-8. PubMed ID: 9137354
    [No Abstract]   [Full Text] [Related]  

  • 5. RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia.
    Hofstra RM; Sijmons RH; Stelwagen T; Stulp RP; Kousseff BG; Lips CJ; Steijlen PM; Van Voorst Vader PC; Buys CH
    J Invest Dermatol; 1996 Aug; 107(2):215-8. PubMed ID: 8757765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and therapy of medullary thyroid carcinoma].
    Obara T; Kanbe M; Iihara M; Yamaguchi K; Futami H
    Nihon Naika Gakkai Zasshi; 1997 Jul; 86(7):1202-8. PubMed ID: 9379100
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
    Ponder BA
    Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple endocrine neoplasia type 2a. Genetic screening in the familial tumor syndrome].
    Ambrosch A; Pfützner A; Ponder BA; Beyer J; Luley C; Lehnert H
    Dtsch Med Wochenschr; 1995 Apr; 120(17):615-9. PubMed ID: 7736960
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA testing for more sophisticated clinical management of multiple endocrine neoplasia type 2 (MEN 2).
    Futami H
    Jpn J Clin Oncol; 1998 Oct; 28(10):588-9. PubMed ID: 9839496
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular mechanisms of RET activation in human neoplasia.
    Santoro M; Carlomagno F; Melillo RM; Billaud M; Vecchio G; Fusco A
    J Endocrinol Invest; 1999 Nov; 22(10):811-9. PubMed ID: 10614534
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.
    Mulligan LM; Ponder BA
    J Clin Endocrinol Metab; 1995 Jul; 80(7):1989-95. PubMed ID: 7608246
    [No Abstract]   [Full Text] [Related]  

  • 14. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
    Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
    J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal molecular diagnosis of RET proto-oncogene mutation in multiple endocrine neoplasia type 2A.
    Huang SM; Tao BL; Tzeng CC; Liu HT; Wang WP
    J Formos Med Assoc; 1997 Jul; 96(7):542-4. PubMed ID: 9262059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual vignette. Multiple endocrine neoplasia type 2A (MEN2A) associated with cutaneous lichen amyloidosis.
    Bonbassei GJ
    Endocr Pract; 2003; 9(6):570. PubMed ID: 14758805
    [No Abstract]   [Full Text] [Related]  

  • 17. A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?
    Sáez ME; Ruiz A; Cebrián A; Morales F; Robledo M; Antiñolo G; Borrego S
    Hum Mutat; 2000 Jan; 15(1):122. PubMed ID: 10612852
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple endocrine neoplasia: the paradigm of the arrival of molecular biology in clinical practice.
    Gonçalves LM
    Rev Port Cardiol; 2000 Jan; 19(1):33-8. PubMed ID: 10731789
    [No Abstract]   [Full Text] [Related]  

  • 19. A de novo mutation of the RET proto-oncogene in a patient with MEN 2A.
    Mulligan LM; Eng C; Healey CS; Ponder MA; Feldman GL; Li P; Jackson CE; Ponder BA
    Hum Mol Genet; 1994 Jun; 3(6):1007-8. PubMed ID: 7951212
    [No Abstract]   [Full Text] [Related]  

  • 20. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.